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Plasmodium vivax is the most widespread and the second most prevalent malaria-causing species in the world. Current mea-
sures used to control the transmission of this disease would benefit from the development of an efficacious vaccine. In the case of
the deadly parasite P. falciparum, the recombinant RTS,S vaccine containing the circumsporozoite antigen (CSP) consistently
protects 30 to 50% of human volunteers against infection and is undergoing phase III clinical trials in Africa with similar effi-
cacy. These findings encouraged us to develop a P. vivax vaccine containing the three circulating allelic forms of P. vivax CSP.
Toward this goal, we generated three recombinant bacterial proteins representing the CSP alleles, as well as a hybrid polypeptide
called PvCSP-All-CSP-epitopes. This hybrid contains the conserved N and C termini of P. vivax CSP and the three variant repeat
domains in tandem.We also generated simian and human recombinant replication-defective adenovirus vectors expressing
PvCSP-All-CSP-epitopes. Mice immunized with the mixture of recombinant proteins in a formulation containing the adjuvant
poly(I·C) developed high and long-lasting serum IgG titers comparable to those elicited by proteins emulsified in complete
Freund’s adjuvant. Antibody titers were similar in mice immunized with homologous (protein-protein) and heterologous (ade-
novirus-protein) vaccine regimens. The antibodies recognized the three allelic forms of CSP, reacted to the repeated and nonre-
peated regions of CSP, and recognized sporozoites expressing the alleles VK210 and VK247. The vaccine formulations described
in this work should be useful for the further development of an anti-P. vivax vaccine.
Human malaria infection starts when an Anopheles mosquitoinjects sporozoites of Plasmodium species into the skin of a
person. The sporozoites traverse the skin, enter the blood circula-
tion, and infect hepatocytes. While sporozoites are in the skin or
migrating to the liver, their infectivity can be abolished by anti-
bodies against the circumsporozoite antigen (CSP). The neutral-
izing antibodies are predominantly, but not exclusively, directed
against the immunodominant B epitopes in the CSP repeat do-
main (reviewed in reference 1).
Multiple trials with experimental animals and more recently
with humans provide a solid basis for the use of vaccines against
CSP to prevent malaria. Thus far, the only vaccine against the
deadly Plasmodium falciparum parasite tested in a phase III clini-
cal trial is RTS,S, a fusion protein between portions of CSP and the
hepatitis B surface antigen (S) that is administered in a powerful
adjuvant system (AS), either an oil-in-water emulsion (AS02) or a
liposomal suspension (AS01). These adjuvants contain mono-
phosphoryl lipid A (a detoxified form of lipopolysaccharide
[LPS]) and QS21 (purified saponin from Quillaja saponaria).
Clinical phase IIa trials with naive, vaccinated volunteers who
were challenged with bites from mosquitoes infected with P. fal-
ciparum reported protective efficacies of 32 to 50%. Protective
immunity largely correlated with the serum levels of specific IgG
antibodies against the repeats in the CSP antigen and, to a lesser
extent, with the frequency of CD4T cells expressing two ormore
of the following cytokines: interleukin-2 (IL-2), tumor necrosis
factor alpha (TNF-), and gamma interferon (IFN-) (2).
One of these formulations (RTS,S/AS01E) is currently being
tested in a large phase III clinical trial of African children living in
areas where malaria is endemic. The results reported from this
trial indicate 49.5 or 30.1% protective efficacy during a 14-month
period postvaccination in 5- to 17-month-old or 6- to 12-week-
old African children, respectively (3, 4). These trials and previous
human trials have established that immunodominant CSP is a
worthwhile candidate antigen to be included in future vaccine
formulations to combat malaria infections, including infections
with P. vivax.
P. vivax is the most widespread malaria-causing species in the
world and is the second most prevalent. It is estimated that more
than 2.8 billion people are at risk of contracting P. vivax infection
(5). Nevertheless, only three clinical trials based on subunit P.
vivax vaccines have been completed (http://www.clinicaltrials
.gov/). One complication of P. vivax vaccine development is that,
in contrast to P. falciparum, different allelic forms of P. vivax CSP
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have been described. The two most common CSP alleles are
VK210 and VK247 (6, 7). A third allelic form exists at a low fre-
quency (8–12). The main variation among these allelic forms is in
the central repeat region of CSP, which is a possible target of
neutralizing antibodies.
To generate a vaccine with universal coverage against P. vivax
malaria strains, we tested a prime-boost regimen using recombi-
nant proteins and adenovirus vectors expressing epitopes from
the three CSP alleles as antigens. We used two approaches to gen-
erate these vaccines. The first consisted of mixing recombinant
proteins expressing the three CSP alleles to generate a vaccine.
Additionally, we generated a single recombinant fusion protein
called PvCSP-All-CS-epitopes that contains epitopes from the
three P. vivaxCSP alleles.We primed animals with either a simian
or a human recombinant replication-defective adenovirus vector
expressing PvCSP-All-CS-epitopes in some experiments. In most
of the experiments, recombinant antigens were administered in a
formulation containing the adjuvant poly(I·C).We compared the
immunogenicities of homologous (protein-protein) and heterol-
ogous (adenovirus-protein) immunization regimens.We primar-
ily measured the magnitude and longevity of the serum IgG
responses to all of CSP and the CSP domains. In selected experi-
ments, we also evaluated the cell-mediated immune response to
CSP.
MATERIALS AND METHODS
Ethics statement. This study was carried out in strict accordance with the
recommendations provided by Guide for the Care and Use of Laboratory
Animals of the Brazilian National Council of Animal Experimentation
(http://www.cobea.org.br/). The protocol was approved by the Commit-
tee on the Ethics of Animal Experiments of the Institutional Animal Care
and Use Committee at the Federal University of Sao Paulo (ID number
CEP 0307/09). Six- to 8-week-old isogenic female C57BL/6 (H-2b) mice
were maintained under specific-pathogen-free conditions were pur-
chased from the Center for Development of Experimental Models for
Medicine and Biology (Federal University of São Paulo, São Paulo, Bra-
zil). tlr4 knockout (tlr4/) C57BL/6 mice were kindly provided by Shi-
zuo Akira, Osaka University, Osaka, Japan (13). Experiments were ap-
proved by the Ethics Committee in Research of the Federal University of
São Paulo and São Paulo Hospital (CEP 0307/09).
Generationof recombinant bacterial proteins containing sequences
of the CSP antigen of P. vivax. For immunization, recombinant bacterial
proteins representing the different allelic forms of P. vivax CSP were ex-
pressed and purified as described below. These recombinant proteins
were named His6-PvCSP-VK210, His6-PvCSP-VK247, His6-PvCSP-
Vivax-like, and His6-PvCSP-All-CSP-epitopes. The deduced amino acid
sequences of the recombinant proteins are depicted in Fig. 1B. Codon-
optimized synthetic genes were purchased from GenScript Inc. that con-
tained the sequences of nucleotides PvCSP-vk210, PvCSP-vk247, PvCSP-
Vivax-like, and PvCSP-All-CSP-epitopes. These genes were subcloned
into the commercial pET28a expression vector (Novagen), expressed, and
purified as follows. Recombinant Escherichia coli BL21(DE3) (Novagen)
transformed with each recombinant plasmid was cultivated at 37°C in
flasks containing Luria broth (LB) and kanamycin (30 g/ml). Protein
expressionwas induced at an optical density at 600 nm(OD600) of 0.6with
0.1 mM isopropyl--D-thiogalactopyranoside (Invitrogen) for 4 h. After
centrifugation, bacteria were lysed on ice with an ultrasonic processor
(Sonics and Materials Inc. Vibra Cell VCX 750) in phosphate buffer (pH
8.0) with 1.0 mg/ml lysozyme (Sigma) and 1 mM phenylmethylsulfonyl
fluoride (Sigma). The bacterial lysate was centrifuged, and the superna-
tant was resuspended in 8 M urea (Invitrogen). After being boiled at
100°C for 15 min, the proteins were applied to a column with Ni2-
nitrilotriacetic acid-agarose resin (Qiagen). After several washes, bound
proteins were eluted with 0.5 M imidazole (Sigma). The eluted protein
was dialyzed against 20 mM Tris-HCl (pH 8.0), and the recombinant
proteins were purified by ion-exchange chromatography with a Resource
Q column (GE Healthcare) coupled to a fast protein liquid chromatogra-
phy system (GE Healthcare). Fractions containing the recombinant pro-
teins with a high degree of purity were pooled and incubated with poly-
myxin B-agarose (Sigma) overnight. Unbound material was extensively
dialyzed against phosphate-buffered saline (PBS; pH 7.2). Protein con-
centration was determined with the Bradford assay and by SDS-PAGE
analyses. LPS determination was done with the E-TOXATE kit (Sigma).
Tests were performed with different dilutions of each sample, and the
results demonstrated that the LPS contamination varied between 300 and
3,000 endotoxin U/mg of purified protein.
In addition, for epitope mapping, we used His6-FliC, His6-FliC-
PvCSP-VK210, His6-FliC-PvCSP-VK247, and His6-FliC-PvCSP-Vivax-
like. These proteins were generated as described in detail in reference 14.
Finally, a recombinant protein devoid of the repeat regions expressing the
N- andC-terminal regions of CSPwas generated and namedHis6-PvCSP-
No-repeats. These recombinant proteins were expressed and purified as
described previously (15).
Generation of recombinant replication-defective adenovirus vec-
tors expressing sequences encoding the CSP antigens of P. vivax. Re-
combinant replication-defective human adenovirus serotype 5 (AdHu5)
and chimpanzee adenovirus serotype 68 (AdC68) vectors were generated,
purified, quality controlled, and titrated as previously described (16), with
the sequence ad-PvCSP. For the deduced amino acid sequence of the CS
antigen, see Fig. 6B.
Immunization regimens. Mice were given three immunizations 3
weeks apart subcutaneously (s.c.) in the two hind footpads with a final
volume of 50 l for each footpad (first dose) and a final volume of 100 l
at the base of the tail (second and third doses). For each dose, the indicated
amount of protein was used. Complete Freund’s adjuvant (CFA) and
incomplete Freund’s adjuvant (IFA) (Sigma) were emulsified with the
protein antigens (1:1, vol/vol) prior to injection. For the CFA-IFA immu-
nization regimens, CFA was used for the first dose and IFA was used for
subsequent doses. As additional adjuvants, 50 g of high-molecular-
weight poly(I·C) (InvivoGen) or Hiltonol (PolyICL, Oncovir Inc., kindly
provided by A. M. Salazar) was mixed with the protein antigens in a final
volume of 100 l.
Recombinant adenovirus vectors were injected intramuscularly (i.m.)
into the tibialis anterioris with a final volume of 50 l for each leg.
Peptide synthesis. Synthetic peptides were purchased fromGenScript
(Piscataway, NJ). Peptide purity was higher than 90%. Peptide identities
were confirmed by a Q-TOFMicro equipped with an electrospray ioniza-
tion source (Micromass UK Ltd., Manchester, United Kingdom).
Immunological assays. Serum IgG anti-P. vivax CSP antibodies were
detected by enzyme-linked immunosorbent assay (ELISA) as previously
described (14, 15). The recombinant proteins (100 to 200 ng/well) were
used as the solid-phase bound antigen. A peroxidase-conjugated goat an-
ti-mouse IgG (Sigma) was applied at a final dilution of 1:1,000, while the
sera from mice were tested at serial dilutions starting with 1:200. Specific
antibody titers were determined as the highest dilution yielding an OD492
higher than 0.1. In parallel, we performed a standard curve of purified
mouse IgG (Sigma) by using the anti-Fab (Sigma) capture antibody ac-
cording to the protocol suggested in reference 17.
Detection of IgG subclass responses was performed as described
above, except that the secondary antibody was specific for mouse IgG1,
IgG2b, and IgG2c (Southern Technologies). The results are presented as
means standard deviations (SD).
Monoclonal antibodies (MAbs) against P. vivax CS proteins repre-
senting the allelic forms VK210 (2F2) and VK247 (2E10.E9; Alan Co-
chrane, unpublished results) were generated after immunization with ra-
diation-attenuated sporozoites (18). The hybridomas used were obtained
from the Malaria Research and Reference Reagent Resource Center
(MR4). Polyclonal antibodies against the P. vivax-like epitopes were ob-
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tained from C57BL/6 mice immunized with the His6-FliC-PvCSP-Vivax-
like antigen as described previously (14). MAbs to the His tag were pur-
chased from GE Healthcare Systems.
Cell-mediated immunity assays. Splenocytes collected from im-
munized C57BL/6 mice were used for enzyme-linked immunospot
(ELISPOT) assays to measure the secretion of IFN- and for in vivo cyto-
toxicity assays. These assays were performed as in our previous studies
(19, 20).
For assays of the expression of the intracellular cytokines (ICs) IFN-
and TNF-, splenocytes collected from C57BL/6 mice were treated with
ACK buffer (NH4Cl, 0.15 M; KHCO3, 10 mM; Na2-EDTA, 0.1 mM; pH
7.4) to lyse the erythrocytes. ICs were evaluated after in vitro culture of
splenocytes in the presence or absence of the indicated antigenic stimulus.
Cells were washed in cell culture medium consisting of RPMI 1640 me-
dium, pH 7.4, supplemented with 10 mM HEPES, 0.2% sodium bicar-
bonate, 59 mg/liter of penicillin, 133 mg/liter of streptomycin, and 10%
HyClone fetal bovine serum (HyClone, Logan, UT). The viability of the
cells was evaluated with 0.2% trypan blue. The cell concentration was
adjusted to 5 	 106/ml of cell culture medium containing anti-CD28 (2
g/ml), brefeldin A (10 g/ml), and monensin (5 g/ml; BD Pharmin-
gen). To half of the cultures, a final concentration of 10 g/ml of the
indicated peptides or recombinant proteins or 2g/ml of concanavalin A
(ConA; Sigma) was added. The cells were cultivated in V-bottom 96-well
plates (Corning) in a final volume of 200 l in duplicate at 37°C in a
humid environment containing 5% CO2. After a 12-h incubation, cells
were stained for surface markers with peridinin chlorophyll protein-
FIG 1 Production and purification of P. vivax CSP recombinant proteins. (A) Schematic representation of the P. vivax CSP antigen and the sequences of the
repeat regions present in each allelic form (PvCSP-VK210, PvCSP-VK247, or PvCSP-Vivax-like). (B) The predicted amino acid sequence of each recombinant
protein. (C) Recombinant proteins were purified by affinity purification followed by anion-exchange chromatography and separated by SDS-PAGE under
reducing conditions. Lanes: a, His6-PvCSP-VK210; b, His6-PvCSP-VK247; c, His6-PvCSP-Vivax-like; d, His6-PvCSP-All-CSP-epitopes. Each lane was loaded
with 1 g of protein.
Plasmodium vivax CS Protein Vaccine Candidates
February 2014 Volume 82 Number 2 iai.asm.org 795
Cy5.5-labeled anti-CD4 (clone RM4-5) or PECy7-labeled CD8 (clone 53-
6.7) on ice for 20 min. To detect IFN- and TNF- by intracellular stain-
ing, cells were then washed twice in buffer containing PBS, 0.5% bovine
serum albumin (BSA), and 2 mM EDTA, fixed in 4% PBS-paraformalde-
hyde solution for 10 min, and permeabilized for 15 min in a solution of
PBS, 0.1% BSA, and 0.1% saponin. After being washed twice, cells were
stained for intracellular markers with fluorescein isothiocyanate (FITC)-
labeled anti-IL-2 antibody (JES6-5H4), allophycocyanin-labeled anti-
IFN- antibody (cloneXMG1.2), and phycoerythrin -labeled anti-TNF-
antibody (clone MP6-XT22) for 20 min on ice. Finally, cells were washed
twice and fixed in 1% PBS-paraformaldehyde. At least 300,000 cells were
acquired on a BD FacsCanto flow cytometer and then analyzed with
FlowJo (Tree Star, Ashland, OR).
P. vivax slide preparation and indirect immunofluorescence assay
(IIA). Sera from animals immunized simultaneously with the three re-
combinant proteins (a mixture of the His6-PvCSP-VK210, His6-PvCSP-
VK247, and His6-PvCSP-Vivax-like proteins) in a formulation contain-
ing the adjuvant poly(I·C) or from mice that received a heterologous
prime-boost vaccination regimen (adenovirus-protein mixture) were se-
lected for the immunofluorescence assay. P. vivax sporozoites expressing
PvCSP VK210 or VK247 were obtained as previously described (21, 22).
Slides containing sporozoites fixed in air were blocked with PBS–3% BSA
for 30 min at room temperature. Slides were incubated in a humid cham-
ber for 1 h at room temperature with 1 g/ml of the MAb 2F2 (anti-
PvCSP-VK210 MAb) as a positive control or with sera from mice were
immunized with adjuvant only diluted 1:1,000 as a negative control. Ad-
ditionally, we used sera from immunized animals that had been diluted
1:100, 1:1,000, 1:10,000, and 1:100,000. After immersion in PBS to wash
the slides, the slides were incubated for 1 h at room temperature with
PBS–3% BSA containing FITC-conjugated goat antibody reactive against
murine IgG (Kirkegaard & Perry Laboratories, Inc.) at a concentration of
0.02 mg/ml. The slides were washed in PBS containing 50 mM glycine,
slightly dried, andmounted with buffered glycerol.We analyzed the slides
under an optical microscope with fluorescence at a magnification of	100.
Statistical analyses. One-way analysis of variance (ANOVA) and
Tukey’s honestly significant difference (HSD) test were used to compare
the differences between the serum IgG titers of the different groups.
Nucleotide sequence accession numbers. Sequences for PvCSP-
vk210, PvCSP-vk247, PvCSP-Vivax-like, PvCSP-All-CSP-epitopes, and
ad-PvCSP were deposited into GenBank under accession numbers
KF971719 to KF971723, respectively.
RESULTS
Production and purification of P. vivax CSP recombinant pro-
teins and recognition by MAbs. Figure 1A shows a schematic
representation of the P. vivax CSP antigen and the sequences of
the repeated regions present in the allelic forms of CSP (VK210,
VK247, and P. vivax-like). Codon-optimized genes were synthe-
sized that contained the same coding regions for the N and C
termini. The central domain encoded the different allelic forms of
the P. vivax CSP protein. These genes were expressed as recombi-
nant fusion proteins representing each individual allelic form of
theP. vivaxCSP antigen linked to a hexahistidine (His6) tag. These
antigens were named His6-PvCSP-VK210, His6-PvCSP-VK247,
and His6-PvCSP-Vivax-like. The predicted amino acid sequence
of each recombinant fusion protein is shown in Fig. 1B. In addi-
tion, a fourth synthetic gene was constructed encoding the three
distinct allelic forms expressed as a single fusion polypeptide
called His6-PvCSP-All-CSP-epitopes (Fig. 1B).
Recombinant proteins were purified as described in Materials
andMethods and separated by SDS-PAGE under reducing condi-
tions. Although the predicted molecular masses of the recombi-
nant proteins were 35,207.42, 33,633.48, 33,878.94, and 34,346.40
Da, the apparent molecular masses determined by SDS-PAGE
varied from approximately 50,000 to 55,000 Da (Fig. 1C).
To determine whether the polypeptides retained the epitopes
recognized by specific MAbs generated against radiation-attenu-
ated P. vivax sporozoites, we performed an ELISAwith each of the
four recombinant proteins bound to the plates. As depicted in Fig.
2A, all four recombinant proteins were recognized well by a MAb
against the His tag. The MAb against allelic variant VK210 (2F2)
recognized recombinant proteins His6-PvCSP-VK210 and His6-
PvCSP-All-CSP-epitopes equally well. This MAb extensively
cross-reacted with the recombinant protein His6-PvCSP-Vivax-
like and reacted to a minor extent with His6-PvCSP-VK247
(Fig. 2B).
The MAb against the VK247 allele (2E10.E9) reacted with the
recombinant proteins His6-PvCSP-VK247 and His6-PvCSP-All-
CSP-epitopes equally well. No cross-reactivity with the recombi-
nant protein His6-PvCSP-VK210 or His6-PvCSP-Vivax-like was
detected (Fig. 2C). Finally, polyclonal antibodies to the P. vivax-
like repeat region reacted equally well with the recombinant pro-
teins His6-PvCSP-Vivax-like and His6-PvCSP-All-CS-epitopes.
No cross-reactivity was detected with the recombinant protein
His6-PvCSP-VK210 or His6-PvCSP-VK247 (Fig. 2D). On the ba-
sis of these results, we concluded that the repeat epitopes present
in the different allelic variants of P. vivax were preserved in the
bacterial recombinant proteins. Most relevant, the recombinant
His6-PvCSP-All-CSP-epitopes were equally recognized by all
three different MAbs and polyclonal sera used, indicating the
presence of the three distinct epitopes in this fusion polypeptide.
Induction of specific antibody responses inmice immunized
with recombinant P. vivax CSP antigens. The serum IgG re-
sponses to P. vivax CSP antigens were determined in C57BL/6
mice immunized s.c. with purified proteins in the presence of the
adjuvant poly(I·C) or emulsified in complete/incomplete Freund’s
adjuvant (CFA-IFA).Micewere immunizedwith three doses 21 days
apart, and the antibody titerswere analyzed according to the timeline
described in Fig. 3A. Twelve mouse groups were immunized with
(i) poly(I·C), (ii) poly(I·C) plus His6-PvCSP-VK210 (10 g/
dose/mouse), (iii) poly(I·C) plus His6-PvCSP-VK247 (10 g/dose/
mouse), (iv) poly(I·C) plus His6-PvCSP-Vivax-like (10 g/dose/
mouse), (v) poly(I·C) plus a protein mixture (His6-PvCSP-VK210,
His6-PvCSP-VK247, and His6-PvCSP-Vivax-like, 30 g/dose/
mouse), (vi) poly(I·C) plus His6-PvCSP-All-CSP-epitopes (30g/
dose/mouse), (vii) CFA-IFA, (viii) CFA-IFA plus His6-PvCSP-VK210
(10 g/dose/mouse), (ix) CFA-IFA plus His6-PvCSP-VK247 (10 g/
dose/mouse), (x) CFA-IFA plus His6-PvCSP-Vivax-like (10 g/
dose/mouse), (xi) CFA-IFA plus a protein mixture (His6-PvCSP-
VK210, His6-PvCSP-VK247, and His6-PvCSP-Vivax-like, 30 g/
dose/mouse), and (xii) CFA-IFA plus His6-PvCSP-All-CSP-
epitopes (30 g/dose/mouse).
At the indicated days, the titer of antibody to each individual
allelic form of P. vivaxCSP was determined by ELISA. In all of the
groups of mice immunized with a formulation containing recom-
binant CSP antigen and adjuvant, the antibody titers were above
105 after the second dose. According to our standard curve of
mouse IgG, this antibody titer represents approximately 50g/ml
of specific IgG. After the third dose, in some cases, we observed an
enhancement of these titers to 106. High antibody titers lasted
for a period of 183 days after the first immunization. At that time,
titers were still in the range of 105 to 106.
By comparing the antibody titers of groups ofmice immunized
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with the recombinant antigens in the presence of the adjuvant
poly(I·C) (Fig. 3B to D), we found that immunization with the
protein mixture generated higher antibody titers than immuniza-
tion with each individual protein or with the proteinHis6-PvCSP-
All-CSP-epitopes (P
 0.01 in all cases for the period of 183 days).
In contrast, all groups of mice immunized with the recombinant
CSP antigens emulsified in CFA-IFA produced similar antibody
titers (Fig. 3E toG; no statistically significant difference in all cases
for the period of 183 days).
We then compared groups of mice injected with the protein
mixture or His6-PvCSP-All-CSP-epitopes in formulations con-
taining the adjuvants poly(I·C) or CFA-IFA. We found that im-
munization with the protein mixture generated similar antibody
titers when emulsified in CFA-IFA or mixed with the adjuvant
poly(I·C) (no statistically significant difference). In contrast, mice
immunized with His6-PvCSP-All-CSP-epitopes emulsified in
CFA-IFA displayed significantly higher antibody titers than ani-
mals injected with the antigen in the presence of poly(I·C). These
experiments allowed us to conclude that immunization with the
protein mixture was superior to immunization with His6-PvCSP-
All-CSP-epitopes when poly(I·C) was used as the adjuvant. Addi-
tionally, we concluded that when using the protein mixture in the
presence of poly(I·C), the antibody titers could be as high and long
lasting as the titers generated by this same protein mixture emul-
sified in CFA-IFA.
Although the anti-PvCSP-specific IgG antibody titers after im-
munization with the protein mixture in formulations containing
CFA-IFA or poly(I·C) were equally high, these immune responses
differed significantly in terms of the subclasses of IgG that were
elicited. Responses generated in the presence of CFA-IFA resulted
in predominately IgG1 rather than IgG2c (ratio of 19.1), while
responses generated in the presence of poly(I·C) resulted in an
IgG1-to-IgG2c subclass ratio of 0.95.
To compare the potency of poly(I·C) with the commercially
available Hiltonol [poly(ICLC)] that is being used in human trials
(23), we performed side-by-side comparison experiments by im-
munizing mice with (i) poly(I·C), (ii) poly(I·C) plus a protein
mixture (His6-PvCSP-VK210, His6-PvCSP-VK247, and His6-
PvCSP-Vivax-like, 30 g/dose/mouse), or (iii) Hiltonol plus the
same protein mixture. We observed that the antibody titers of mice
immunized with the protein mixture in the presence of either adju-
vant elicited similarly high antibody titers that lasted until at least day
160 (no statistically significant difference; data not shown).
We then determined whether lower doses of the recombinant
protein mixture could be as effective in eliciting high and sus-
tained antibody immune responses. For this purpose, mice were
immunized side by side with 10 or 1 g of each of the three re-
combinant proteins in the presence of the adjuvant poly(I·C).
Mice immunized with 30 or 3 g of the total protein mixture
FIG 2 Antibody recognition of P. vivax CSP recombinant proteins. ELISAs were performed with each of the four PvCSP recombinant (Rec.) proteins bound to
the plates to determine whether the polypeptides retained the epitopes recognized by specificMAbs generated against radiation-attenuated P. vivax sporozoites.
(A)MAb against the His tag. (B)MAb 2F2 specific to the allelic form PvCSP-VK210. (C)MAb 2E10.E9 specific to the allelic form PvCSP-VK247. (D) Polyclonal
antibodies to the PvCSP-Vivax-like repeat region.
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responded equally well. Antibody titers above 105 lasted for more
than 200 days (Fig. 4A to C; no statistically significant difference).
Purified bacterial recombinant proteins often contain traces
of contaminating LPS that can interfere with immunogenicity.
To show that contaminating LPS was not influencing the im-
munogenicity results, we performed a side-by-side comparison
of the antibody immune responses to the protein mixture when
administered to tlr4/ or tlr4/ mice in the presence of
poly(I·C). After immunization, both mouse strains responded
equally well for the entire 177-day observation period (Fig. 5A
to C; no statistically significant difference). These observations
ruled out any possible interference from LPS contamination in
our samples.
Induction of specific antibody responses inmice immunized
with recombinant adenovirus vectors expressing P. vivax CSP
as part of a heterologous prime-boost regimen for vaccination.
In addition to the recombinant proteins, we generated two recom-
binant replication-defective adenovirus vectors expressing the
gene encoding the PvCSP-All-CSP-epitopes antigen. Schematic
representations of the deduced amino acid sequences of the pro-
teins expressed by these recombinant adenovirus vectors are de-
picted in Fig. 6A and B. Antigen expression was confirmed by
infection of HEK-293 cells and immunofluorescence analyses
(data not shown). The recombinant adenoviruses were designated
AdC68-PvCSP and AdHu5-PvCSP. Immunization of C57BL/6
mice with 2	 107 PFU of either of these recombinant adenovirus
vectors elicited specific IgG antibodies against each individual al-
lelic form of PvCSP. This dose was determined experimentally as
the minimum dose to elicit antibody titers higher than 103. After
21 days, titers of antibodies to all three different alleles of recom-
binant PvCSP were in the range of 104. No statistically significant
difference was observed in the serum IgG titers between the
groups of mice vaccinated with AdC68-PvCSP or AdHu5-PvCSP
(Fig. 6C). As expected, controlmice injectedwith the same dose of
AdHu5-gal did not generate any P. vivax-specific antibodies.
However, at a later time point, the antibody titers of mice immu-
FIG 3 Induction of specific antibody responses inmice immunized with recombinant P. vivaxCSP antigens. (A)Mice were immunized with three doses 21 days
apart, and the antibody titers were analyzed according to the timeline shown. The serum IgG responses to P. vivaxCS antigens were determined in C57BL/6mice
immunized s.c. with the purified proteins in a formulation containing the adjuvant poly(I·C) (B toD) or emulsified inCFAor IFA (E toG).Micewere immunized
with His6-PvCSP-VK210 (10g/dose/mouse), His6-PvCSP-VK247 (10g/dose/mouse), His6-PvCSP-Vivax-like (10g/dose/mouse), a proteinmixture (His6-
PvCSP-VK210, His6-PvCSP-VK247, andHis6-PvCSP-Vivax-like, 30g/dose/mouse), or His6-PvCSP-All-CS-epitopes (30g/dose/mouse). Serum IgG titers of
antibodies against recombinant proteins representing each allelic form of PvCSP were measured as indicated. The results are expressed as means SD (n 6).
Statistical comparisons by one-way ANOVA of the antibody titers from mice immunized with formulations containing the adjuvant poly(I·C) (B to D) show
significantly higher antibody levels in animals immunized with the proteinmixture (P
 0.01, asterisks). Comparisons of the antibody titers of mice immunized
with formulations containing the adjuvant CFA-IFA and recombinant proteins did not show statistically significant differences.
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nized with AdC68-PvCSP were higher than those of animals im-
munized with AdHu5-PvCSP (P
 0.05; Fig. 6D).
To test whether recombinant adenovirus vectors could be used
as priming immunogens in a heterologous prime-boost regimen,
mice primed with the adenovirus vector were boosted s.c. 42 days
after being primed with a protein mixture (His6-PvCSP-VK210,
His6-PvCSP-VK247, and His6-PvCSP-Vivax-like 3 g/dose/
mouse) in a formulation containing poly(I·C). Serum titers of IgG
antibodies against all three allelic forms of PvCSP at day 63 inmice
primed with AdC68-PvCSP (G5) or AdHu5-PvCSP (G6) and
boosted with the protein mixture were significantly higher than
the titers in control groups (G1, G2, G3, and G4) (P 
 0.05,
Fig. 6D). No statistically significant differences were scored be-
tween mouse groups G5 and G6. These results provide evidence
that priming with AdC68-PvCSP and AdHu5-PvCSP improves
antibody responses upon subsequent immunization with the re-
combinant protein mixture.
These samemice described above received a second boost with
a protein mixture in a formulation containing poly(I·C) or with
only adjuvant (control), as depicted in Fig. 7A. We followed the
titers of specific serum IgGs against the different allelic forms of
PvCSP for 178 days (Fig. 7B to D). Antibody titers in the different
mouse groups immunized (boosted) twice with the recombinant
protein mixture were equally high, and we did not detect statisti-
cally significant differences among groups G4, G5, and G6 (no
statistically significant difference in all cases). Not only were the
titers of anti-PvCSP-specific IgG after immunization equally high,
but these immune responses were equally sustained, with high
antibody titers persisting until day 178. Additionally, these re-
sponses did not differ significantly in terms of the subclasses of
IgG that were elicited. The IgG1/IgG2c ratios of groupsG4 andG5
were 0.95 and 1.125, respectively.
These experiments allow us to conclude that recombinant ad-
enoviruses expressing the PvCSP protein can successfully be used
in a heterologous prime-boost protocol for vaccination.However,
no significant impact on the serum IgG antibody titers was ob-
served when we used either the homologous (protein-protein) or
the heterologous (adenovirus-protein) regimen.
Specificity of the antibodies elicitedby thehomologous (pro-
tein-protein) or heterologous (adenoviruses/protein) regimen.
We then studied the specificity of the antibodies against PvCSP.
We selected for the sera frommice that had been immunized with
the homologous (protein-protein) or heterologous (adenovirus-
protein) regimen. To aid in the determination of the specificity of
anti-PvCSP serum IgG antibodies, we used a number of recombi-
nant proteins containing different portions of the antigen. Sche-
matic representations of the recombinant proteins used and the
antibody titers are depicted in Fig. 8A.
We found that antibodies from mice immunized with either
the homologous or the heterologous regimen reacted with all of
the recombinant proteins containing different portions of the
three distinct allelic forms of the PvCSP antigen. These antibodies
reacted with each repeat domain expressed as a part of a fusion
protein in the C-terminal region of FliC. Themice also had signif-
icant titers of antibodies to a recombinant protein expressing the
FIG 4 Induction of specific antibody responses in mice immunized with recombinant P. vivax CSP antigens. C57BL/6 mice were immunized at 30 or 3
g/dose/mouse with a formulation containing a protein mixture (His6-PvCSP-VK210, His6-PvCSP-VK247, and His6-PvCSP-Vivax-like) in the presence of the
adjuvant poly(I·C). The immunizations were s.c. with three doses given 21 days apart according to the timeline shown in Fig. 3A. Serum IgG titers of antibodies
against recombinant proteins representing each allelic form of PvCSP were measured as indicated. Mice immunized with 30 (inverted triangles) and 3 (squares)
g/dose/mouse of the proteinmixture responded equally well according to statistical comparisons (one-way ANOVA, no statistically significant difference). The
results as expressed as means SD (n 6).
FIG 5 Induction of specific antibody responses in tlr4/ mice immunized
with recombinantP. vivaxCS antigens.Micewere immunizedwith three doses
21 days apart according to the protocol and timeline shown in Fig. 3A. The
serum IgG responses against P. vivax CSP recombinant proteins were deter-
mined in tlr4/ and tlr4/ mice immunized with formulations containing
poly(I·C) and a PvCSP mixture (His6-PvCSP-VK210, His6-PvCSP-VK247,
and His6-PvCSP-Vivax-like, 3 g/dose/mouse) or control recombinant FliC
(10g/dose/mouse). tlr4/ (inverted triangles) and tlr4/ (diamonds)mice
immunized with the PvCSP protein mixture responded well according to sta-
tistical comparisons (one-way ANOVA, no statistically significant difference).
The results are expressed as means SD (n 6).
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N- and C-terminal regions but not the repeat region of the PvCSP
antigen (His6-PvCSP-No-repeats). As expected, however, the
maximal reactivity was directed against the recombinant proteins
containing all of PvCSP (Fig. 8B). We concluded that both the
repeated and nonrepeated regions of PvCSP are targets for anti-
bodies.
Finally, we determined whether sera from mice immunized
with the homologous or heterologous immunization regimens
reacted with P. vivax sporozoites in immunofluorescence assays.
We observed that sera from both groups reacted to sporozoites of
the P. vivaxVK247 strain at a titer of 1:1,000 and in the case of the
homologous immunization also at a titer of 1:10,000 (Fig. 9A).
Antibody recognition was specific, as control sera from mice im-
munized with either the adjuvant poly(I·C) or AdHu5-gal/
poly(I·C) did not react, even at a 1:100 dilution (Fig. 9B). We also
confirmed that sera from both groups of mice that were immu-
nized with a formulation containing the protein mixture and
poly(I·C) reacted to sporozoites of the VK210 strain at a dilution
of 1:10,000 (Fig. 9C).
Cell-mediated immune responses. To determine whether the
vaccination protocols elicited T cell-mediated immune responses,
we employed several methods of analyses. Spleen cells from mice
immunized with either the homologous or the heterologous reg-
imen were stimulated in vitro with recombinant proteins or over-
lapping synthetic peptides (15-mers) covering all of PvCSP. We
measured IFN- secretion by ELISPOT assay, by IC expression
assays, and by detection of the cytokine in the supernatants. We
also attempted to detect IL-2 and TNF by IC expression assays.
Finally, we also used an in vivo cytotoxicity assay to estimate the
presence of cytotoxic T lymphocytes in vaccinated mice (24). The
results were negative in most cases independently of the timing of
the analyses. Positive controls performed in parallel with experi-
mental samples were consistently successful (data not shown).
Examples of these studies are depicted in Fig. 10 and 11. Splenic
cells of mice immunized with the heterologous or homologous
prime-and-boost regimen (described in Fig. 10A) were restimu-
lated in culture with the recombinant proteins or synthetic pep-
tides spanning the entire N- or C-terminal region of P. vivax CSP
(Fig. 10B). Significant differences in the frequencies of IFN-,
IL-2, or TNF-a in CD4 or CD8 cells in the experimental and
control groups were not detected (Fig. 10C and D).
In parallel, these cells were subjected to ELISPOT assays. Like-
FIG 6 Induction of specific antibody responses in mice immunized with recombinant adenoviruses expressing P. vivax CSP as part of a heterologous prime-
boost regimen of vaccination. (A and B) Schematic representations and deduced amino acid (aa) sequences of the PvCSP-All-CSP-epitopes expressed by
recombinant replication-defective simian or human adenovirus. (C) C57BL/6 mice were immunized i.m. at 2	 107 PFU/mouse with AdHu5-gal (control),
AdC68-PvCSP, or AdHu5-PvCSP. Serum titers of IgG against recombinant proteins of each allelic form of PvCSP were determined 21 days later as indicated.
Mice immunized with AdC68-PvCS andAdHu5-PvCS responded equally well according to statistical comparisons (one-way ANOVA, no statistically significant
difference [NS]). The results are expressed asmeans SD (n 5). (D)Mice were boosted s.c. 42 days after being primedwith a formulation containing a protein
mixture (His6-PvCSP-VK210, His6-PvCSP-VK247, and His6-PvCSP-Vivax-like, 3g/dose/mouse) in the presence of poly(I·C). The titers of specific antibodies
to the different allelic forms of PvCSP were measured at day 63. According to statistical comparisons (one-way ANOVA, Tukey’s HSD test), mice immunized with
AdC68-PvCS and AdHu5-PvCS and boosted with a protein mixture (G5 and G6) had serum IgG antibody titers higher than those of the other groups, as shown.
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wise in the IC expression assay experiments, significant differ-
ences in the frequencies of IFN--producing cells in the experi-
mental and control groups were not detected (Fig. 11). One
peptide only representing the repeat region of PvCSP of the P.
vivax-like allele elicited amodest number of specific spot-forming
cells. This peptide possibly represents a T cell epitope for C57BL/6
mice. We were able to obtain a stronger immune response by
using IFA for immunization (data not shown).We concluded that
although we were able to obtain high levels of antibody produc-
tion following immunization, this response was not paralleled by
high levels of T cell-mediated immunity.
DISCUSSION
In the present study, we tested whether recombinant proteins and
adenovirus vectors could be used for the development a universal
vaccine against P. vivax malaria. Using homologous or heterolo-
gous prime-boost immunization regimens, we were able to suc-
cessfully elicit high titers of antibodies recognizing the three allelic
forms of the PvCSP antigen. This malaria vaccine formulation
could be used either as a proteinmixture containing His6-PvCSP-
VK210, His6-PvCSP-VK247, andHis6-PvCSP-Vivax-like or a sin-
gle recombinant protein containing epitopes of all three different
allelic forms in a single fusion polypeptide (His6-PvCSP-All-CSP-
epitopes). However, in the presence of poly(I·C), we found the
proteinmixture to bemore immunogenic. This improved immu-
nogenicity was not observed when the antigens were emulsified in
CFA-IFA. The precise reasons for these differences are not clear.
Nevertheless, these data highlight the importance of testing differ-
ent formulations for vaccine selection.
Both homologous and heterologous vaccine protocols elicited
specific antibody titers that were as high as those elicited following
immunizationwith recombinant proteins emulsified in CFA-IFA.
In addition, the antibody responses induced by both protocols
were long lasting and significant titers were observed during the
180-day period of the study. We have focused our efforts on
inducing persistently high titers of specific antibodies against the
CSP antigen. Antibodies against CSP have been described previ-
ously as a critical mechanism of antisporozoite immunity in di-
verse malaria models (reviewed in reference 1). On the basis of
phase II human trials performed with the RTS,S/AS candidate
FIG 7 Induction of specific antibody responses in mice immunized with a heterologous (adenovirus-protein) or a homologous (protein-protein) vaccination
regimen. (A) C57BL/6 mice were immunized with three doses of the indicated immunogens, and the antibody titers were analyzed according to the timeline
shown. The first dose consisted of 2	 107 PFU/mouse of AdHu5-gal (control), AdC68-PvCSP, or AdHu5-PvCSP administered i.m. The first and second boosts
consisted of a formulation containing a protein mixture (His6-PvCSP-VK210, His6-PvCSP-VK247, and His6-PvCSP-Vivax-like, 3 g/dose/mouse) in the
presence of poly(I·C). (B) Serum IgG titers against His6-PvCSP-VK210. (C) Serum IgG titers against His6-PvCSP-VK247. (D) Serum IgG titers against
His6-PvCSP-Vivax-like. Mice immunized with AdHu5-gal, AdC68-PvCS, and AdHu5-PvCS and boosted twice with a formulation containing a protein
mixture in the presence of poly(I·C) (G4, G5, and G6) responded equally well according to statistical comparisons (one-way ANOVA, Tukey’s HSD test, no
statistically significant difference). The results are expressed as means SD (n 5).
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vaccine, antibodies continue to be the factor that strongly corre-
lates with sterile immunity. In RTS,S/AS-vaccinated individuals
who were experimentally challenged with P. falciparum sporozo-
ites by mosquito bite, vaccine efficacy was correlated with higher
titers of antibodies against CSP and sporozoites (2). Similarly,
phase II vaccine trials performed with African children reported a
nonlinear relationship between the titers of antibodies against
CSP and a lower incidence of malaria (25).
Several antiparasitic mechanisms have been described that are
mediated by antibodies against CSP. First, antibodies reduce the
sporozoite inoculumandparasite viability during amosquito bite.
With an experimental rodent model, it has been shown that an
immune complex formed during the mosquito bite reduces the
number of sporozoites deposited during feeding (26). The para-
sites injected into immune mice were immobilized and not capa-
ble of invading dermal blood vessels (26). When the sporozoites
are inoculated intravenously, thus bypassing the skin, anti-CSP
antibodies efficiently block the infection of hepatocytes (26). The
inhibition of hepatocyte infectionmay be due to a reduction of the
sporozoites’ ability to move or attach to hepatocytes (27–29).
The specificity of the inhibitory antibodies for themalaria CSP
antigen was initially assigned to the central repeat domain (30). In
the case of P. vivax, this postulate was recently confirmed by the
use of a transgenic P. berghei sporozoite expressing the repeat
domain from the VK210 strain. In vivo parasite infectivity in mice
was drastically inhibited by the passive transfer of a MAb against
the VK210 repeats (31). These observations further confirm sim-
FIG 8 Specificity of the antibodies elicited by a homologous (protein-protein) or a heterologous (adenovirus-protein) immunization regimen. (A) Schematic
representation of each recombinant protein used as a substrate bound to the plates in the ELISA. AA, amino acid; term, terminus. (B) Serum IgG antibodies from
mice immunized with the homologous [protein-protein with poly(I·C)] or the heterologous (AdC68-PvCSP/protein mixture) regimen. The detailed immuni-
zation protocol is described in the legends to Fig. 3 (homologous) and 7 (heterologous). Sera were collected 2 weeks after the third dose was given. The results are
expressed as means S.D (n 5).
FIG 9 IIA for the recognition of the native protein PvCSP. Pools of sera from
mice immunized with the homologous [protein-protein with poly(I·C)] and
heterologous (AdC68-PvCSP/protein mixture) regimens were used. The de-
tailed immunization protocol is described in the legends to Fig. 3 (homolo-
gous) and 7 (heterologous).
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FIG10 Cell-mediated immunity ofmice immunizedwith recombinantP. vivaxCSP antigens. (A)C57BL/6micewere immunizedwith three doses given 14 days
apart, and IC expression assays were performed according to the timeline shown. (B) Twenty-six overlapping peptides spanning the entire sequence of the N or
C terminus of PvCSP were used to stimulate splenocytes. AA, amino acid. (C and D) G1 mice (control) were primed i.m. at 2 	 108 PFU/mouse with
AdHu5-b-gal and boosted s.c. twice with poly(I·C). G2 mice were primed i.m. at 2 	 108 PFU/mouse with AdC68-PvCSP and boosted twice with a protein
mixture (His6-PvCSP-VK210, His6-PvCSP-VK247, and His6-PvCSP-Vivax-like, 30 g/dose/mouse) in the presence of poly(I·C). G3 mice were primed and
boosted with a protein mixture (His6-PvCSP-VK210, His6-PvCSP-VK247, and His6-PvCSP-Vivax-like, 30g/dose/mouse). Fourteen days later, splenic cells of
these mice were cultured in the presence of anti-CD28 antibody, monensin, and brefeldin A with or without the peptides or recombinant proteins or ConA as
indicated. The PvCS-VK210, PvCS-VK247, and PvCS-Vivax-like peptides represent the repeat regions of the allelic variants. After 12 h, cells were stained with
anti-CD4, anti-CD8, anti-IL-2, anti-IFN-, and anti-TNF- antibodies. The results are expressed as the total frequency (%) of CD4 or CD8 cells stained for
each molecule. Results were obtained from pooled cells from five mice.
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ilar data from other parasites, which showed that the repeat do-
main of CSP is a target of neutralizing antibodies.
In addition to the repeat domain, in the case of theP. vivaxCSP
protein, humans immunized with long synthetic peptides repre-
senting the N and C termini of CSP generated antibodies that can
inhibit sporozoite invasion in vitro (32). These results indicate
that vaccines that elicit high titers of antibodies against different
regions of PvCSP should be pursued. In the vaccination protocols
described here, we generated high titers of antibodies against all
three allelic forms of the PvCSP protein that reacted with different
domains of the protein.
IIA analyses with sporozoites of P. vivax strains VK210 and
VK247 demonstrated that these vaccine-elicited antibodies can
recognize the native CSP on sporozoites. However, the ability of
these antibodies to neutralize sporozoites in vivo has yet to be
evaluated with transgenic parasites (31).
In addition to antibodies, CD4 and CD8 T cells have been
described as powerful mediators of preerythrocytic stage elimina-
tion in rodent experimental models (reviewed in references 32–
38). In fact, a number of T cell epitopes have been described by us
and others in CSP (reviewed in references 32–38). The results
obtained with the mouse model have fueled a number of human
trials with plasmid DNA, recombinant viruses, and, more re-
cently, radiation-attenuated sporozoites as vaccine formulations.
Unfortunately, in spite of the enthusiasm generated by the mouse
model, T cell-based vaccines against preerythrocytic stages of ma-
laria have provided sterile immunity against infection with P. fal-
ciparum to only a few vaccinated individuals to date (39–44). The
precise reason for this failure is not clear. Perhaps the frequency of
T cells generated by the different vaccine protocols was not suffi-
cient, as these T cells have to patrol the entire human liver. In fact,
since the first reports of adoptive T cell transfermore than 20 years
ago, it has been known that large numbers of multifunctional
effector CD8 T cells must be transferred to a mouse to provide
sterile immunity (45–47).More recently, elegant studies using the
mouse model have confirmed that a large number of multifunc-
tional effector CD8 T cells must be generated to provide sterile
protection (48).
The development of candidate vaccines against preerythrocytic
stages of P. vivax has been performed mostly with preclinical im-
munizationmodels (mice and nonhuman primates; 49–51). Only
three phase I clinical trials of recombinant proteins or long syn-
thetic peptides against this parasite have been reported (52–54).
The reagents and protocols described in the present study, when
used in homologous or heterologous regimens, can be immedi-
ately transferred to humans. Poly(ICLC) is currently being tested
for human use (23). Similarly, recombinant human replication-
defective adenoviruses of serotype 5 are being used in multiple
human trials (55–58).
The fact that we did not detect significant differences in anti-
body titers or cell-mediated immunity when using either the ho-
mologous or the heterologous vaccination regimen should not be
considered a failure of the second. Considering that our ultimate
goal is human trials, the use of a recombinant adenovirus vector
may still improve the immune response by the presence of human
T-cell epitopes. On the basis of that, we believe that the formula-
tions described here provide new P. vivax vaccine candidates with
universal coverage that warrant further clinical testing.
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